# A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.

> **NCT00154336** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 50 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Methotrexate
- **DRUG:** Imatinib Placebo

## Key facts

- **NCT ID:** NCT00154336
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-08
- **Final completion:** 2005-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00154336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00154336, "A Study of Imatinib 400 mg Once Daily in Combination With Methotrexate in the Treatment of Rheumatoid Arthritis.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00154336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*